| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/02/2009 | WO2009039944A1 Phenothiazine derivative having a double bond, method for the production thereof, and use thereof as a pharmaceutical |
| 04/02/2009 | WO2009020317A3 Stabilized antioxidant particles, composition comprising the same and method for preparing the same |
| 04/02/2009 | WO2009020314A3 Stabilized alpha-lipoic acid particles, composition comprising the same and method for preparing the same |
| 04/02/2009 | WO2009014910A3 N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders |
| 04/02/2009 | WO2009010299A8 Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| 04/02/2009 | WO2009007412A3 Age deglycation |
| 04/02/2009 | WO2008104994A3 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
| 04/02/2009 | WO2008094905A3 Encapsulated hdl mimetic peptides |
| 04/02/2009 | WO2008005914A3 Novel glucokinase activators and methods of using same |
| 04/02/2009 | US20090088442 Prophylactic/therapeutic agent for abnormalities of sugar/lipid metabolism |
| 04/02/2009 | US20090088438 NEW TYROSINE DERIVATIVES AS PPARy MODULATORS |
| 04/02/2009 | US20090088431 Heteroaromatic Compounds as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase |
| 04/02/2009 | US20090088430 hydroxysteroid reductase inhibitors such as 4-{(R)-3-[3,5-Dichloro-4'-(4-trifluoromethyl-piperidine-1-carbonyl)-biphenyl-4-ylmethyl]-2-oxo-pyrrolidin-1-yl}-piperidine-1-carboxylic acid methyl ester, used for treating diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia and metabolic syndrome |
| 04/02/2009 | US20090088428 (R)-3-(3,5-Dichloro-4'-morpholin-4-yl-biphenyl-4-ylmethyl)-1-(4,5,6,7-tetrahydro-1H-benzoimidazol-5-yl)-pyrrolidin-2-one for treating diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome |
| 04/02/2009 | US20090088425 Glucocorticoid receptor antagonists |
| 04/02/2009 | US20090088419 Pyridyl acetic acid compounds |
| 04/02/2009 | US20090088388 Peptides for Use In Treating Obesity |
| 04/02/2009 | US20090088387 Composition for long-acting peptide analogs |
| 04/02/2009 | US20090088383 Gh secretagogues and uses thereof |
| 04/02/2009 | US20090088380 Ghrh analogs and therapeutic uses thereof |
| 04/02/2009 | US20090088369 Glp-1 and methods for treating diabetes |
| 04/02/2009 | US20090087504 Method for treating diabetic complications |
| 04/02/2009 | US20090087500 Guava leaf extract powder and method for production thereof |
| 04/02/2009 | US20090087483 Oral dosage combination pharmaceutical packaging |
| 04/02/2009 | US20090087479 Orally bioavailable lipid-based constructs |
| 04/02/2009 | US20090087436 Compositions and methods for treating diseases |
| 04/02/2009 | US20090087420 Stable solution of reduced coenzyme q |
| 04/02/2009 | DE102007040798A1 Herb mixture, useful e.g. to slow the aging process, comprises e.g. Crocus sativus, Elettaria cardamomum, Cinnamomum zeylanicum, Hedychium spicatum, Terminalia chebula, Trichosanthes dioica, Coleus forskolin and Berberis aristata |
| 04/02/2009 | CA2701053A1 Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors |
| 04/02/2009 | CA2700277A1 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives |
| 04/02/2009 | CA2700088A1 Quinolone derivative |
| 04/02/2009 | CA2699718A1 Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
| 04/02/2009 | CA2699328A1 Pyrrolidines and piperidines as orexin receptor antagonists |
| 04/02/2009 | CA2699244A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |
| 04/02/2009 | CA2699241A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699177A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699170A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699154A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699153A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699100A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699077A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699073A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699069A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699068A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699065A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699055A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699054A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699052A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699049A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699047A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699039A1 Use of bpp-b as a therapeutic agent |
| 04/02/2009 | CA2699035A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 04/02/2009 | CA2699000A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-arg-gly-asp-asn-pro-oh as a therapeutic agent |
| 04/02/2009 | CA2698775A1 Big gastrin i as a therapeutic agent |
| 04/02/2009 | CA2698772A1 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent |
| 04/02/2009 | CA2698768A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698764A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698762A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | CA2698751A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698673A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698672A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2696113A1 Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| 04/01/2009 | EP2042591A1 Erythropoietin-producing organoid precursor, method of constructing the same and method of treating erythropoietin-related disease |
| 04/01/2009 | EP2042510A2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleid acid (siNA) |
| 04/01/2009 | EP2042196A2 Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| 04/01/2009 | EP2042175A1 Dose regimens of CB1-Receptor ligands in the treatment of obesity |
| 04/01/2009 | EP2042170A1 Creatine composition and use |
| 04/01/2009 | EP2042163A1 Pharmaceutical compositions comprising fluvastatin |
| 04/01/2009 | EP2041137A2 Pyrrolopyrimidines for pharmaceutical compositions |
| 04/01/2009 | EP2041123A2 Fused cyclic compounds |
| 04/01/2009 | EP2041114A2 Inhibitors of advanced glycation end products |
| 04/01/2009 | EP2041108A1 4-hydroxythiobenzamide derivatives of drugs |
| 04/01/2009 | EP2041101A1 Crystalline form of (trans-4- [ ( { 5- [ (3, 4 -di fluorophenyl) amino]-1,3, 4-oxadiazol-2-yl}carbonyl) amino]ph enyl } cyclohexyl) acetic acid |
| 04/01/2009 | EP2041100A1 Substituted 5- phenylamino- 1, 3, 4-oxadiaz0l-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase |
| 04/01/2009 | EP2041099A1 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors |
| 04/01/2009 | EP2040755A1 Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity |
| 04/01/2009 | EP2040737A1 Epidermal growth factor increasing insulin secretion and lowering blood glucose |
| 04/01/2009 | EP2040736A1 New formulation for increasing bioavailability of neurturin |
| 04/01/2009 | EP2040704A2 Pharmaceutical compositions comprising implitapide and methods of using same |
| 04/01/2009 | EP2040702A1 Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them |
| 04/01/2009 | EP2040701A2 Aminoindazole urea derivatives |
| 04/01/2009 | EP2040566A1 Milk fever |
| 04/01/2009 | EP1836151B1 Vitamin d receptor modulators |
| 04/01/2009 | EP1721616B1 Protein hydrolysate for treating fatigue |
| 04/01/2009 | EP1521744B1 Arylsulphonamide derivatives and use thereof as b1 bradykinin receptor antagonists |
| 04/01/2009 | EP1349873B1 Modulation of il-2- and il-15-mediated t cell responses |
| 04/01/2009 | EP1137666B9 Glp-1 analogues |
| 04/01/2009 | CN101400663A Polymorphic forms of { 2-methyl-4- [4-methyl-2- (trifluoromethylphenyl) thiazol-5-methylthiol phenoxy}-acetic acid |
| 04/01/2009 | CN101400660A Triazole derivative or salt thereof |
| 04/01/2009 | CN101400659A Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity |
| 04/01/2009 | CN101400367A Methods for treating unwanted weight loss or eating disorders by administering a TRKB agonist |
| 04/01/2009 | CN101400344A Composition for improving cellular membrane composition and function |
| 04/01/2009 | CN101400270A Compositions for food or beverage with improved hygroscopicity |
| 04/01/2009 | CN101397327A Method for preparing dihydro ginsenoside Rg2 and use thereof |
| 04/01/2009 | CN101397315A Tonka bean camphor glycosides compounds, preparation method thereof and medicament composition and use thereof |
| 04/01/2009 | CN101397300A Dipeptidase-IV inhibitor derivates |
| 04/01/2009 | CN101397298A Acidamide substituted pyrrole[2,3-b] pyridines compounds, preparation method and use thereof |
| 04/01/2009 | CN101397294A N-substituted pyrrolidine derivates and uses thereof |
| 04/01/2009 | CN101397271A Method for preparing vitamin B6 |
| 04/01/2009 | CN101396559A Fat regulation |